Trial · NCT03934099

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099, Phase 2, Completed, LG Chem; results first posted 2025-12-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia. Trials, record NCT03934099. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03934099

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
NCT number: NCT03934099
Status: Completed
Phases: Phase 2
Enrollment: 156 participants, actual
Lead sponsor: LG Chem
Conditions: Gout, Hyperuricemia
Interventions: LC350189 formulated capsule, Placebo
First posted: 2019-05-01
Last updated: 2025-12-03
Results first posted: 2025-12-03

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	Day 84	sUA level was measured at Day 84
Secondary	Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	Day 84	sUA level was measured at Day 84
Secondary	Maximum Percent Reduction in sUA (Serum Uric Acid) Level	Up to Day 84	sUA level was measured at Day 1, 14, 28, 56, and 84

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	Day 84	Percentage of participants	NUMBER
SECONDARY	Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	Day 84	Percentage of participants	NUMBER
SECONDARY	Maximum Percent Reduction in sUA (Serum Uric Acid) Level	Up to Day 84	Percentage of reduction in sUA	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	LC350189 50mg	47.1		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	LC350189 100mg	44.7		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	LC350189 200mg	62.2		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84	Placebo	2.9		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	LC350189 50mg	58.8		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	LC350189 100mg	63.2		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	LC350189 200mg	78.4		Percentage of participants
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84	Placebo	2.9		Percentage of participants
Maximum Percent Reduction in sUA (Serum Uric Acid) Level	LC350189 50mg	-46.67	Standard Deviation 13.560	Percentage of reduction in sUA
Maximum Percent Reduction in sUA (Serum Uric Acid) Level	LC350189 100mg	-50.64	Standard Deviation 19.127	Percentage of reduction in sUA

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	LC350189 50mg	34
Overall Study	STARTED	LC350189 100mg	38
Overall Study	STARTED	LC350189 200mg	37
Overall Study	STARTED	Placebo	34
Overall Study	COMPLETED	LC350189 50mg	30
Overall Study	COMPLETED	LC350189 100mg	32
Overall Study	COMPLETED	LC350189 200mg	34
Overall Study	COMPLETED	Placebo	32
Overall Study	NOT COMPLETED	LC350189 50mg	4
Overall Study	NOT COMPLETED	LC350189 100mg	6

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events32

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrehoea	Gastrointestinal disorders	LC350189 50mg	1	34	1
other	Diarrehoea	Gastrointestinal disorders	LC350189 100mg	2	38	2
other	Diarrehoea	Gastrointestinal disorders	LC350189 200mg	1	37	1
other	Diarrehoea	Gastrointestinal disorders	Placebo	1	34	1
other	Gout flare	Metabolism and nutrition disorders	LC350189 50mg	9	34	16
other	Gout flare	Metabolism and nutrition disorders	LC350189 100mg	6	38	11
other	Gout flare	Metabolism and nutrition disorders	LC350189 200mg	10	37	15
other	Gout flare	Metabolism and nutrition disorders	Placebo	6	34	6
other	Blood pressure increased	Investigations	LC350189 50mg	0	34	0
other	Blood pressure increased	Investigations	LC350189 100mg	1	38	1

1 to 10 of 32Source ClinicalTrials.gov

See all 32 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	LC350189 50mg	0	34
Total, all-cause mortality	LC350189 100mg	0	38
Total, all-cause mortality	LC350189 200mg	0	37
Total, all-cause mortality	Placebo	0	34
Total, other adverse events	LC350189 50mg	15	34
Total, other adverse events	LC350189 100mg	13	38
Total, other adverse events	LC350189 200mg	21	37
Total, other adverse events	Placebo	8	34
Total, serious adverse events	LC350189 50mg	0	34
Total, serious adverse events	LC350189 100mg	0	38

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03934099

GET https://conductscience.org/api/trials/v1/NCT03934099/events?page=2

API reference For AI assistants